⌘K

Login Start Free

Home/Filings/4/0001185185-24-000264

4//SEC Filing

GRIMALDI CLAUDIA 4

Accession 0001185185-24-000264

CIK 0001326205other

View on SEC.gov Company Profile

Filed

Mar 14, 8:00 PM ET

Accepted

Mar 15, 9:27 PM ET

Size

23.3 KB

Accession

0001185185-24-000264

Insider Transaction Report

Form 4

Period: 2024-03-13

IGC Pharma, Inc.IGC

GRIMALDI CLAUDIA

Director

Transactions

Exercise/Conversion
Common Stock
2024-03-13+100,000→ 942,154 total
Exercise/Conversion
Restricted Stock Units
2024-03-13−83,333→ 0 total
→ Common Stock (83,333 underlying)
Exercise/Conversion
Restricted Stock Units
2024-03-13−100,000→ 200,000 total
→ Common Stock (100,000 underlying)
Exercise/Conversion
Common Stock
2024-03-13+58,333→ 842,154 total
Exercise/Conversion
Restricted Stock Units
2024-03-13−58,334→ 58,332 total
→ Common Stock (58,334 underlying)
Exercise/Conversion
Common Stock
2024-03-13+83,333→ 783,821 total
Exercise/Conversion
Common Stock
2024-03-13+95,000→ 1,037,154 total
Exercise/Conversion
Restricted Stock Units
2024-03-13−95,000→ 285,000 total
Exp: 2033-03-31→ Common Stock (95,000 underlying)
Award
Options
2024-03-13+360,000→ 360,000 total
→ Common Stock (360,000 underlying)
Award
Options
2024-03-13+550,000→ 550,000 total
Exp: 2034-03-31→ Common Stock (550,000 underlying)

Footnotes (7)

[F1]On July 19, 2021, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 2022.
[F2]On May 25, 2022, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 2023.
[F3]On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 2024.
[F4]On June 20, 2023, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved.
[F5]Each restricted stock unit represents a right to receive one share of IGC common stock.
[F6]On March 13, 2024, the Reporting Person was granted Options subject to vesting equally over three years starting on March 2025. The exercise price is $0.26.
[F7]On March 13, 2024, the Reporting Person was granted Options subject to vesting according to specific milestones set by the Company's Board of Directors. The Options vest when milestones are achieved. The exercise price is $0.26.

Documents

1 file

4
ownership.xmlPrimary

Issuer

IGC Pharma, Inc.

CIK 0001326205

Entity typeother

Related Parties

1

filerCIK 0001745853

Filing Metadata

Form type: 4
Filed: Mar 14, 8:00 PM ET
Accepted: Mar 15, 9:27 PM ET
Size: 23.3 KB

View on SEC.gov